Avonex Pen (Biogen Idec) is FDA approved for relapsing Multiple Sclerosis

The FDA has approved two separate dosing innovations designed to improve the treatment experience for patients receiving once-a-week Avonex from Biogen Idec for relapsing forms of Multiple Sclerosis (MS). Avonex Pen, the first intramuscular (IM) autoinjector approved for MS, incorporates a smaller needle and easier administration to help patients reduce anxiety about Avonex self-injection. A new dose titration regimen, which gradually escalates the dose of Avonex treatment initiation, reduces the incidence and severity of flu-like symptoms that can occur at the beginning of therapy.Avonex Pen is EU approved.